PT2382474E - Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica - Google Patents

Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica Download PDF

Info

Publication number
PT2382474E
PT2382474E PT107041154T PT10704115T PT2382474E PT 2382474 E PT2382474 E PT 2382474E PT 107041154 T PT107041154 T PT 107041154T PT 10704115 T PT10704115 T PT 10704115T PT 2382474 E PT2382474 E PT 2382474E
Authority
PT
Portugal
Prior art keywords
biomarcer
icam
soluble
preparation
therapeutic response
Prior art date
Application number
PT107041154T
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce Acres
Bérangère Marie-Bastien
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PT2382474E publication Critical patent/PT2382474E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525ICAM molecules, e.g. CD50, CD54, CD102
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT107041154T 2009-01-20 2010-01-18 Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica PT2382474E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305044 2009-01-20
EP09305294 2009-04-07

Publications (1)

Publication Number Publication Date
PT2382474E true PT2382474E (pt) 2015-06-03

Family

ID=42028081

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107041154T PT2382474E (pt) 2009-01-20 2010-01-18 Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica

Country Status (23)

Country Link
US (2) US20110312525A1 (https=)
EP (1) EP2382474B1 (https=)
JP (1) JP5379243B2 (https=)
KR (1) KR20110116016A (https=)
CN (1) CN102292638B (https=)
AU (1) AU2010206195B2 (https=)
BR (1) BRPI1006901A2 (https=)
CA (1) CA2749192A1 (https=)
CO (1) CO6390020A2 (https=)
CR (1) CR20110438A (https=)
DK (1) DK2382474T3 (https=)
ES (1) ES2536747T3 (https=)
HR (1) HRP20150470T1 (https=)
HU (1) HUE025015T2 (https=)
IL (1) IL213098A (https=)
MX (1) MX2011007386A (https=)
NZ (1) NZ593749A (https=)
PL (1) PL2382474T3 (https=)
PT (1) PT2382474E (https=)
SG (2) SG196837A1 (https=)
TW (1) TWI440854B (https=)
WO (1) WO2010084100A1 (https=)
ZA (1) ZA201105271B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103175959B (zh) * 2013-02-28 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破免疫层析试纸的制备方法
CN103235134B (zh) * 2013-05-08 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破的免疫层析试纸及其制备方法
CN103698537A (zh) * 2014-01-06 2014-04-02 天津医科大学总医院 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法
JP2021514678A (ja) * 2018-03-06 2021-06-17 ペップバックス・インコーポレイテッド 核酸分子およびそれを使用する方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
ATE128727T1 (de) 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2362367C (en) 1999-02-04 2004-08-03 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
US7381536B2 (en) 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
SG173065A1 (en) 2011-08-29
US20110312525A1 (en) 2011-12-22
AU2010206195B2 (en) 2016-03-10
TW201031917A (en) 2010-09-01
CA2749192A1 (en) 2010-07-29
NZ593749A (en) 2012-05-25
TWI440854B (zh) 2014-06-11
HK1161643A1 (en) 2012-07-27
CO6390020A2 (es) 2012-02-29
KR20110116016A (ko) 2011-10-24
ES2536747T3 (es) 2015-05-28
CN102292638A (zh) 2011-12-21
PL2382474T3 (pl) 2015-08-31
CR20110438A (es) 2011-12-28
IL213098A0 (en) 2011-07-31
ZA201105271B (en) 2012-03-28
HRP20150470T1 (hr) 2015-06-05
US20140023686A1 (en) 2014-01-23
IL213098A (en) 2015-08-31
AU2010206195A1 (en) 2010-07-29
EP2382474B1 (en) 2015-03-04
HUE025015T2 (en) 2016-04-28
RU2011134415A (ru) 2013-02-27
MX2011007386A (es) 2011-08-03
JP2012515893A (ja) 2012-07-12
BRPI1006901A2 (pt) 2016-02-16
DK2382474T3 (en) 2015-04-07
JP5379243B2 (ja) 2013-12-25
EP2382474A1 (en) 2011-11-02
WO2010084100A1 (en) 2010-07-29
CN102292638B (zh) 2014-05-28
SG196837A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
IL245328A0 (en) Pharmaceutical composition
DK2539015T3 (da) Nethindeprotese
HUE059497T2 (hu) Tartószerkezetek szívbillentyû-protézis számára
IL226245A0 (en) History
BR112013009853A2 (pt) cápsula para preparação de uma bebida
EP2646006A4 (en) ARZNEIMITTELDARREICHUNGSFORM
UY33094A (es) Procedimiento para la preparacion de dronedarona
GB201217619D0 (en) Pulsatile drug release
BRPI1007256A2 (pt) cápsula para o preparo de uma bebida
SMT201400069B (it) Formulazione farmaceutica
EP2425827A4 (en) TRANSDERMALES PREPARATION
EP2569042A4 (en) CATHETER SHAPE ADJUSTMENT MECHANISM
EP2442821A4 (en) SAFE ADMINISTRATION OF DESMOPRESSIN
EP2550961A4 (en) SOLID PREPARATION
IT1403793B1 (it) Protesi retinica
BRPI0922653A2 (pt) preparação farmacêutica
EP2399607A4 (en) TRANSDERMALE PREPARATION
EP2826923A4 (en) WATERLESS URINAL
EP2550960A4 (en) SOLID PREPARATION
EP2438917A4 (en) TRANSDERMALES PREPARATION
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
EP2412366A4 (en) SOLID PREPARATION
IT1402029B1 (it) Procedimento per la preparazione di erlotinib
EP2412367A4 (en) SOLID PREPARATION
EP2432320A4 (en) PHARMACEUTICAL QUERCETINE COCKRISTALS